These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 6946459)

  • 1. Homologous species restriction in lysis of erythrocytes by terminal complement proteins.
    Hänsch GM; Hammer CH; Vanguri P; Shin ML
    Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5118-21. PubMed ID: 6946459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
    Hänsch GM; Hammer CH; Mayer MM; Shin ML
    J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
    Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
    J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
    Yamamoto KI
    J Immunol; 1977 Oct; 119(4):1482-5. PubMed ID: 894048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
    J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic action and other metabolic consequences of terminal complement proteins.
    Shin ML; Carney DF
    Prog Allergy; 1988; 40():44-81. PubMed ID: 3281171
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
    Rollins SA; Zhao J; Ninomiya H; Sims PJ
    J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C56 formation in the reaction mixture of isolated complement components through the classical complement pathway.
    Kitamura H; Tsuboi M; Nagaki K
    Int Arch Allergy Appl Immunol; 1985; 78(1):101-7. PubMed ID: 4030125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
    Balkarowa-Ständer J; Rother U; Rauterberg EW
    J Immunol; 1981 Sep; 127(3):1089-93. PubMed ID: 7264298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the alternative pathway of complement activation by a serum factor generated during transplant rejection.
    Spitzer R; Stitzel A; Florio L; Urmson J
    Immunochemistry; 1976 May; 13(5):395-400. PubMed ID: 780264
    [No Abstract]   [Full Text] [Related]  

  • 12. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
    Hu VW; Shin ML
    J Immunol; 1984 Oct; 133(4):2133-7. PubMed ID: 6470486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement lysis of human erythrocytes. II. A unique interaction of human C8 and C9 with paroxysmal nocturnal hemoglobinuria erythrocytes.
    Packman CH; Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1980 Jun; 124(6):2818-23. PubMed ID: 7189536
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretion of the terminal complement proteins, C5-C9, by human platelets.
    Houle JJ; Leddy JP; Rosenfeld SI
    Clin Immunol Immunopathol; 1989 Mar; 50(3):385-93. PubMed ID: 2917425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement lysis of human erythrocytes. III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells.
    Rosenfeld SI; Packman CH; Jenkins DE; Countryman JK; Leddy JP
    J Immunol; 1980 Nov; 125(5):2063-8. PubMed ID: 6776186
    [No Abstract]   [Full Text] [Related]  

  • 17. Restriction of cell lysis by homologous complement: I. An analysis of membrane attack complex formation on target membranes.
    Houle JJ; Hoffmann EM; Esser AF
    Blood; 1988 Feb; 71(2):280-6. PubMed ID: 3337896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemistry and function of the complement system.
    Müller-Eberhard HJ
    Hosp Pract; 1977 Aug; 12(8):33-43. PubMed ID: 892784
    [No Abstract]   [Full Text] [Related]  

  • 19. Number of hits necessary for complement-mediated hemolysis.
    Takeda J; Kozono H; Takata Y; Hong K; Kinoshita T; Sayama K; Tanaka E; Inoue K
    Microbiol Immunol; 1986; 30(5):461-8. PubMed ID: 3747864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deviated lysis: Transfer of complement lytic activity to unsensitized cells II. Generation of the activity by inulin and by antigen antibody complexes.
    Rother U; Hänsch G; Rother K
    Z Immunitatsforsch Immunobiol; 1976 Aug; 151(1):442-54. PubMed ID: 785847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.